Carbapenems: Difference between revisions
No edit summary |
Elcatracho (talk | contribs) |
||
| (5 intermediate revisions by 4 users not shown) | |||
| Line 4: | Line 4: | ||
#[[Imipenem]] | #[[Imipenem]] | ||
#[[Meropenem]] | #[[Meropenem]] | ||
#[[Meropenem-vaborbactam]]<br /> | |||
==Indications== | ==Indications== | ||
* Cephalosporin-resistant nosocomial bacteria | *Cephalosporin-resistant nosocomial bacteria | ||
* Empirical treatment of serious infections in patients who recently received other | *Empirical treatment of serious infections in patients who recently received other beta-lactams | ||
{{Template:Clinically Utilized Antibiotics}} | {{Template:Clinically Utilized Antibiotics}} | ||
| Line 16: | Line 17: | ||
*[[Cephalosporin Cross-reactivity]] | *[[Cephalosporin Cross-reactivity]] | ||
== | ==References== | ||
<references/> | |||
Goodman & Gilman's Pharmacology | Goodman & Gilman's Pharmacology | ||
[[Category: | [[Category:Pharmacology]] | ||
[[Category:ID]] | [[Category:ID]] | ||
Latest revision as of 05:14, 4 January 2022
Types
Indications
- Cephalosporin-resistant nosocomial bacteria
- Empirical treatment of serious infections in patients who recently received other beta-lactams
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
See Also
References
Goodman & Gilman's Pharmacology